HIPRA, an EU-based biopharma company, was developing a recombinant protein vaccine against SARS-COV-2 and was looking for an experienced partner to work with in order to improve the adoption of its vaccine in global markets.
April 30, 2024
Pharmaceutical Partner Introducing New Sterile Vaccine Product
Might interest you
View All Global Health
Enhancing Distributed Manufacturing and Vaccine Distribution through Blow-Fill-Seal Prefilled Drug Delivery Platforms, Upcoming Webinar Hosted by Xtalks
News provided by Xtalks l Feb 10, 2025, 08:30 ET In this free webinar, learn about the core challenges for the immunization community in reaching underserved populations for routine immunizations and outbreak response across diverse regions. Attendees will learn how understanding the...
Global Health
Affordable Prefilled Devices Greatly Expand Access
At Apiject, we believe a higher level of universal expanded access can be achieved by providing injectable medicine and vaccines in single-use, prefilled injectors that are simple, affordable, and can overcome many “Last Mile” challenges.
Global Health
ApiJect Systems Receives Grant to Develop Low-Cost Blow-Fill-Seal Prefilled Injection Device for Low- and Middle-Income Countries
Grant will fund the design and development of an affordable, multi-month contraceptive delivery device to enhance access in Low- and Middle-Income Countries (LMICs). Blow-Fill-Seal will be explored for the container closure and subcutaneous injection delivery system, advancing a concept initially developed by...